Cover Image

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. This analysis aims to evaluate the effects of prolonged lenalidomide induction and isatuximab- or elotuzum...

Full description

Saved in:
Bibliographic Details
Main Authors: Kauer, Joseph (Author) , Freundt, Emma Pauline (Author) , Schmitt, Anita (Author) , Weinhold, Niels (Author) , Mai, Elias K. (Author) , Müller-Tidow, Carsten (Author) , Goldschmidt, Hartmut (Author) , Raab, Marc-Steffen (Author) , Kriegsmann, Katharina (Author) , Sauer, Sandra (Author)
Format: Article (Journal)
Language:English
Published: 21 November 2023
In: BMC cancer
Year: 2023, Volume: 23, Pages: 1-11
ISSN:1471-2407
DOI:10.1186/s12885-023-11507-9
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-023-11507-9
Get full text
Author Notes:Joseph Kauer, Emma P. Freundt, Anita Schmitt, Niels Weinhold, Elias K. Mai, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc S. Raab, Katharina Kriegsmann and Sandra Sauer
Description
Summary:While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. This analysis aims to evaluate the effects of prolonged lenalidomide induction and isatuximab- or elotuzumab-containing quadruplet induction therapies on PBSC mobilization and collection.
Item Description:Gesehen am 04.03.2024
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-023-11507-9

Similar Items